Now Playing
Commentary|Videos|August 25, 2025
Current First-Line Treatment Considerations in Acute Lymphoblastic Leukemia
Author(s)Ibrahim Aldoss, MD, Shira Dinner, MD
Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
The OncFive: Top Oncology Articles for the Week of 8/2
5